MAGEA3 and melanoma: While individualized mRNA vaccines encode for tumor- and host-specific antigens, BNT111 aims to induce expression of the four most frequent melanoma-associated antigens, NY-ESO-1, MAGE-A3, tyrosinase, and TPTE, again utilizing mRNA vaccine technology.